The identification of the best Peg-IFN for chronic HCV is of minor relevance for patients with genotype 2 or 3 since most of them achieve Sustained Virological Response (SVR) with either Peg-IFN formulation [4-6], whereas patients with HCV genotype 1 show a much lower rate of SVR [4-6] and, consequently, are at a higher risk of progression to cirrhosis or hepatocellular carcinoma. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.